University of Minnesota. Driven to Discover.
"I would view the results . . . in an optimistic light," said lead author Richard Davey after the drug showed more than 90% efficacy.
Meanwhile, a different study met with disappointing results for an experimental Ebola drug in the Sierra Leone trial.
Findings include neurologic problems and a potential for virus survival in semen for 18 months.
The child's case is the 4th—including a death—from the same family in Forecariah district.
Also, phase 2 trials just launched for two prime-boost Ebola vaccine regimens.
Funding will be used to continue trials of BCX4430 and prepare for its large-scale manufacture.
The findings clear the way for the next step, which may require a change in venue.
The virus may be more stable than a study in August found.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.